Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression

被引：0
|
作者：
Kun Wang
Xiaoyong Dai
Albert Yu
Chunyan Feng
Kewei Liu
Laiqiang Huang
机构：
[1] Shenzhen Key Laboratory of Gene and Antibody Therapy,
[2] Center for Biotechnology and Biomedicine,undefined
[3] State Key Laboratory of Chemical Oncogenomics,undefined
[4] State Key Laboratory of Health Sciences and Technology,undefined
[5] Precision Medicine and Healthcare Research Center,undefined
[6] Tsinghua-Berkeley Shenzhen Institute (TBSI),undefined
[7] Institute of Biopharmaceutical and Health Engineering,undefined
[8] Shenzhen International Graduate School,undefined
[9] Tsinghua University,undefined
[10] School of Life Sciences,undefined
[11] Tsinghua University,undefined
来源：
Journal of Experimental & Clinical Cancer Research | / 41卷
关键词：
P-PROTACs; FOXM1; Liver cancer; Breast cancer; GLUT1; PD-L1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Expression of PD-L1 in gastric cancer
    Polushkina, T.
    Sotnikova, T.
    Kalinin, D.
    Danilova, N.
    VIRCHOWS ARCHIV, 2024, 485 : S499 - S499
  • [32] PD-L1 Expression in Pancreatic Cancer
    Zheng, Lei
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (06):
  • [33] Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: A new choice for immunotherapy?
    Chen, Tingkai
    Li, Qi
    Liu, Zongliang
    Chen, Yao
    Feng, Feng
    Sun, Haopeng
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 161 : 378 - 398
  • [34] PD-1 AND PD-L1 EXPRESSION ON THE PROGNOSIS OF OVARIAN CANCER
    Li, R. P.
    Li, W. Y.
    Guo, Y. Z.
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2019, 33 (04): : 1161 - 1166
  • [35] Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy
    Li, Chunlin
    Zhang, Nengpan
    Zhou, Jundong
    Ding, Chen
    Jin, Yaqing
    Cui, Xueyuan
    Pu, Kefeng
    Zhu, Yimin
    CANCER IMMUNOLOGY RESEARCH, 2018, 6 (02) : 178 - 188
  • [36] PD-L1 expression in head and neck cancer tissue specimens decreases with time
    Karpathiou, Georgia
    Vincent, Maureen
    Dumollard, Jean Marc
    Mobarki, Mousa
    Peoc'h, Michel
    PATHOLOGY RESEARCH AND PRACTICE, 2022, 237
  • [37] Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
    Festino, Lucia
    Botti, Gerardo
    Lorigan, Paul
    Masucci, Giuseppe V.
    Hipp, Jason D.
    Horak, Christine E.
    Melero, Ignacio
    Ascierto, Paolo A.
    DRUGS, 2016, 76 (09) : 925 - 945
  • [38] Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
    Lucia Festino
    Gerardo Botti
    Paul Lorigan
    Giuseppe V. Masucci
    Jason D. Hipp
    Christine E. Horak
    Ignacio Melero
    Paolo A. Ascierto
    Drugs, 2016, 76 : 925 - 945
  • [39] Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
    Shen, Xian
    Zhao, Bin
    BMJ-BRITISH MEDICAL JOURNAL, 2018, 362
  • [40] Peptide-based immuno-PET/CT monitoring of dynamic PD-L1 expression during glioblastoma radiotherapy
    Wang, Yong
    He, Kewen
    Zhang, Yang
    Chen, Yunhao
    Wang, Shijie
    Zhao, Kunlong
    Liu, Zhiguo
    Hu, Man
    JOURNAL OF PHARMACEUTICAL ANALYSIS, 2025, 15 (03)
12345